Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients.

IF 1.7 Q3 UROLOGY & NEPHROLOGY
Christelle Calen, Seraina Von Moos, Pietro Cippà, Alexandre Mebazaa, Mattia Arrigo
{"title":"Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients.","authors":"Christelle Calen,&nbsp;Seraina Von Moos,&nbsp;Pietro Cippà,&nbsp;Alexandre Mebazaa,&nbsp;Mattia Arrigo","doi":"10.1155/2023/5163548","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Noninvasive identification of haemodialysis patients at high risk of cardiovascular events and death might improve their outcome. Growth differentiation factor 15 is a prognostic biomarker in multiple disease entities, including cardiovascular disease. The aim of this study was to assess the association between plasma GDF-15 and mortality in a cohort of haemodialysis patients.</p><p><strong>Methods: </strong>Circulating GDF-15 was measured in 30 patients after a regular haemodialysis session, followed by a clinical follow-up for all-cause death. Measurements were performed using the Proseek Multiplex Cardiovascular disease panels (Olink Proteomics AB) and validated using the Elecsys GDF-15 electrochemiluminescence immunoassay on a Cobas E801 analyzer (Roche Diagnostics).</p><p><strong>Results: </strong>During a median of 38 months, 9 patients (30%) died. Seven deaths occurred in the group of patients with a circulating GDF-15 above the median and two in the group with lower GDF-15. Mortality was significantly higher in patients with circulating GDF-15 levels above the median, log-rank<i>P</i> = 0.044. The performance of circulating GDF-15 to predict long-term mortality has an area under the ROC curve of 0.76, <i>P</i> = 0.028. Prevalence of most relevant comorbidities and the Charlson comorbidity index were similar across the two groups. A high agreement with a correlation among both diagnostic methods was observed (Spearman's rho = 0.83, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Plasma GDF-15 displays promising prognostic properties for the prediction of long-term survival beyond clinical parameters in patients on maintenance haemodialysis.</p>","PeriodicalId":14177,"journal":{"name":"International Journal of Nephrology","volume":"2023 ","pages":"5163548"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063357/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/5163548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Noninvasive identification of haemodialysis patients at high risk of cardiovascular events and death might improve their outcome. Growth differentiation factor 15 is a prognostic biomarker in multiple disease entities, including cardiovascular disease. The aim of this study was to assess the association between plasma GDF-15 and mortality in a cohort of haemodialysis patients.

Methods: Circulating GDF-15 was measured in 30 patients after a regular haemodialysis session, followed by a clinical follow-up for all-cause death. Measurements were performed using the Proseek Multiplex Cardiovascular disease panels (Olink Proteomics AB) and validated using the Elecsys GDF-15 electrochemiluminescence immunoassay on a Cobas E801 analyzer (Roche Diagnostics).

Results: During a median of 38 months, 9 patients (30%) died. Seven deaths occurred in the group of patients with a circulating GDF-15 above the median and two in the group with lower GDF-15. Mortality was significantly higher in patients with circulating GDF-15 levels above the median, log-rankP = 0.044. The performance of circulating GDF-15 to predict long-term mortality has an area under the ROC curve of 0.76, P = 0.028. Prevalence of most relevant comorbidities and the Charlson comorbidity index were similar across the two groups. A high agreement with a correlation among both diagnostic methods was observed (Spearman's rho = 0.83, P < 0.001).

Conclusion: Plasma GDF-15 displays promising prognostic properties for the prediction of long-term survival beyond clinical parameters in patients on maintenance haemodialysis.

Abstract Image

Abstract Image

生长分化因子15与血液透析患者死亡风险的关系
目的:无创识别高危心血管事件和死亡的血液透析患者可能改善其预后。生长分化因子15是包括心血管疾病在内的多种疾病的预后生物标志物。本研究的目的是评估血液透析患者血浆GDF-15与死亡率之间的关系。方法:在30例定期血液透析患者中测量循环GDF-15,随后进行全因死亡的临床随访。使用Proseek Multiplex心血管疾病面板(Olink Proteomics AB)进行测量,并在Cobas E801分析仪(罗氏诊断)上使用Elecsys GDF-15电化学发光免疫分析法进行验证。结果:在中位38个月期间,9例(30%)患者死亡。在循环GDF-15高于中位数的患者组中有7例死亡,在GDF-15较低的患者组中有2例死亡。循环GDF-15水平高于中位数的患者死亡率明显更高,log-rankP = 0.044。循环GDF-15预测长期死亡率的ROC曲线下面积为0.76,P = 0.028。两组患者最相关合并症的患病率和Charlson合并症指数相似。观察到两种诊断方法之间高度一致的相关性(Spearman’s rho = 0.83, P < 0.001)。结论:血浆GDF-15在预测维持性血液透析患者超出临床参数的长期生存方面具有良好的预后特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Nephrology
International Journal of Nephrology UROLOGY & NEPHROLOGY-
CiteScore
3.40
自引率
4.80%
发文量
44
审稿时长
17 weeks
期刊介绍: International Journal of Nephrology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on the prevention, diagnosis, and management of kidney diseases and associated disorders. The journal welcomes submissions related to cell biology, developmental biology, genetics, immunology, pathology, pathophysiology of renal disease and progression, clinical nephrology, dialysis, and transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信